Séverine Trabado
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Séverine Trabado has a total of 298 co-authors. Here are the top co-authors by number of shared publications:
Sylvie Brailly-Tabard
INSERM U 693, University Paris-South, School of Medicine Paris-South; AP-HP, CHU Bicêtre, Department of Molecular Genetics, Pharmacogenetics and Hormonology, Kremlin-Bicêtre, France
20 shared publications- Philippe Chanson
Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Service d’Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l’Hypophyse (HYPO) , Le Kremlin-Bicêtre 94275
17 shared publications - Jacques Young
Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Service d’Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares du Métabolisme du Calcium et du Phosphate, Centre de Référence des Maladies Rares de l’Hypophyse , Le Kremlin-Bicêtre 94275
14 shared publications - Luigi Maione
Service endocrinologie adultes et maladies de la reproduction, hôpital de Bicêtre, AP-HP, université Paris-Saclay, 78, rue du Général-Leclerc, 94275 Le Kremlin-Bicêtre cedex, France
12 shared publications - Bruno Fève
Service d’Endocrinologie, Hôpital Saint Antoine, INSERM UMR S 938, Centre de Recherche Saint-Antoine, Université Pierre et Marie Curie, Faculté de Médecine, Institut Hospitalo-Universitaire ICAN, Paris, France,
11 shared publications Jacques Young
Assistance Publique-Hôpitaux de Paris (F.G., S.T., J.S., Y.L.B., S.B.-T., J.Y.); F-94010 Créteil, France
10 shared publications
Latest Publications
- 19 September 2023
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 84 (5) , 550
Histone déméthylase KDM1A et régulation épigénétique des fonctions du pancréas endocrine chez le rat
- 19 September 2023
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 84 (5) , 550
Histone déméthylase KDM1A et régulation épigénétique des fonctions du pancréas endocrine chez le rat
- Open Access
- 28 December 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (1) , 497
The MAOA rs979605 Genetic Polymorphism Is Differentially Associated with Clinical Improvement Following Antidepressant Treatment between Male and Female Depressed Patients
Major depressive disorder (MDD) is the leading cause of disability worldwide. Treatment with antidepressant drugs (ATD), which target monoamine neurotransmitters including serotonin (5HT), are only modestly effective. Monoamine oxidase (MAO) metabolizes 5HT to 5-hydroxy indoleacetic acid (5HIAA). Genetic variants in the X-chromosome-linked MAO-encoding genes, MAOA and MAOB, have been associated with clinical improvement following ATD treatment in depressed patients. Our aim was to analyze the association of MAOA and MAOB genetic variants with (1) clinical improvement and (2) the plasma 5HIAA/5HT ratio in 6-month ATD-treated depressed individuals. Clinical (n = 378) and metabolite (n = 148) data were obtained at baseline and up to 6 months after beginning ATD treatment (M6) in patients of METADAP. Mixed-effects models were used to assess the association of variants with the Hamilton Depression Rating Scale (HDRS) score, response and remission rates, and the plasma 5HIAA/5HT ratio. Variant × sex interactions and dominance terms were included to control for X-chromosome-linked factors. The MAOA rs979605 and MAOB rs1799836 polymorphisms were analyzed. The sex × rs979605 interaction was significantly associated with the HDRS score (p = 0.012). At M6, A allele-carrying males had a lower HDRS score (n = 24, 10.9 ± 1.61) compared to AA homozygous females (n = 14, 18.1 ± 1.87; p = 0.0067). The rs1799836 polymorphism was significantly associated with the plasma 5HIAA/5HT ratio (p = 0.018). Overall, CC/C females/males had a lower ratio (n = 44, 2.18 ± 0.28) compared to TT/T females/males (n = 60, 2.79 ± 0.27; p = 0.047). The MAOA rs979605 polymorphism, associated with the HDRS score in a sex-dependent manner, could be a useful biomarker for the response to ATD treatment.
- 28 December 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (1) , 497
Open AccessThe MAOA rs979605 Genetic Polymorphism Is Differentially Associated with Clinical Improvement Following Antidepressant Treatment between Male and Female Depressed Patients
Major depressive disorder (MDD) is the leading cause of disability worldwide. Treatment with antidepressant drugs (ATD), which target monoamine neurotransmitters including serotonin (5HT), are only modestly effective. Monoamine oxidase (MAO) metabolizes 5HT to 5-hydroxy indoleacetic acid (5HIAA). Genetic variants in the X-chromosome-linked MAO-encoding genes, MAOA and MAOB, have been associated with clinical improvement following ATD treatment in depressed patients. Our aim was to analyze the association of MAOA and MAOB genetic variants with (1) clinical improvement and (2) the plasma 5HIAA/5HT ratio in 6-month ATD-treated depressed individuals. Clinical (n = 378) and metabolite (n = 148) data were obtained at baseline and up to 6 months after beginning ATD treatment (M6) in patients of METADAP. Mixed-effects models were used to assess the association of variants with the Hamilton Depression Rating Scale (HDRS) score, response and remission rates, and the plasma 5HIAA/5HT ratio. Variant × sex interactions and dominance terms were included to control for X-chromosome-linked factors. The MAOA rs979605 and MAOB rs1799836 polymorphisms were analyzed. The sex × rs979605 interaction was significantly associated with the HDRS score (p = 0.012). At M6, A allele-carrying males had a lower HDRS score (n = 24, 10.9 ± 1.61) compared to AA homozygous females (n = 14, 18.1 ± 1.87; p = 0.0067). The rs1799836 polymorphism was significantly associated with the plasma 5HIAA/5HT ratio (p = 0.018). Overall, CC/C females/males had a lower ratio (n = 44, 2.18 ± 0.28) compared to TT/T females/males (n = 60, 2.79 ± 0.27; p = 0.047). The MAOA rs979605 polymorphism, associated with the HDRS score in a sex-dependent manner, could be a useful biomarker for the response to ATD treatment.
- 24 September 2021
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 82 (5) , 255
Prévalence de l’obésité et des anomalies du métabolisme glucidique chez les patients adultes avec une hypophosphatémie génétique liée à l’X (XLH)
- 24 September 2021
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 82 (5) , 255
Prévalence de l’obésité et des anomalies du métabolisme glucidique chez les patients adultes avec une hypophosphatémie génétique liée à l’X (XLH)
- 24 September 2021
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 82 (5) , 245
Mise au point et performance de la PTH in situ (PTHis) pour détecter la présence de tissu parathyroïdien chez 121 patients avec hyperparathyroïdie : expérience monocentrique
- 24 September 2021
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 82 (5) , 245
Mise au point et performance de la PTH in situ (PTHis) pour détecter la présence de tissu parathyroïdien chez 121 patients avec hyperparathyroïdie : expérience monocentrique
- 22 January 2021
- Published by Springer Nature in Endocrine
- Vol. 71 (3) , 578-585
Serum insulin-like factor 3 quantification by LC–MS/MS in male patients with hypogonadotropic hypogonadism and Klinefelter syndrome
Purpose Insulin-like factor 3 (INSL3) is an emerging testicular marker, yet larger studies elucidating the clinical role of INSL3 in patients with hypogonadism are lacking. The aim was to describe serum INSL3 concentrations analyzed by LC–MS/MS methodology in males with hypogonadotropic hypogonadism (HH) and Klinefelter syndrome (KS). Methods This was a combined study from two tertiary centers in Denmark and France analyzing INSL3 concentrations by LC–MS/MS. In total, 103 patients with HH and 82 patients with KS were grouped into treated (HH: n = 96; KS: n = 71) or untreated (HH: n = 7; KS: n = 11). Treatment modalities included testosterone and hCG. Serum concentrations and standard deviation (SD) scores of INSL3, total testosterone, and LH according to age and treatment were evaluated. Results In both HH and KS, INSL3 concentrations were low. In HH, INSL3 was low regardless of treatment, except for some hCG-treated patients with normal concentrations. In untreated HH, testosterone was low, while normal to high in most testosterone- and hCG-treated patients. In untreated KS, INSL3 and testosterone concentrations were low to normal, while in testosterone-treated KS, serum INSL3 was low in most patients. INSL3 SD scores were significantly lower in untreated HH than in untreated KS (p = 0.01). Conclusions The dichotomy between lower INSL3 and higher testosterone concentrations, particularly observed in hCG-treated patients with HH, confirms that INSL3 is a different marker of Leydig cell function than testosterone. However, the clinical application of INSL3 in males with hypogonadism remains unclear.
- 22 January 2021
- Published by Springer Nature in Endocrine
- Vol. 71 (3) , 578-585
Serum insulin-like factor 3 quantification by LC–MS/MS in male patients with hypogonadotropic hypogonadism and Klinefelter syndrome
Purpose Insulin-like factor 3 (INSL3) is an emerging testicular marker, yet larger studies elucidating the clinical role of INSL3 in patients with hypogonadism are lacking. The aim was to describe serum INSL3 concentrations analyzed by LC–MS/MS methodology in males with hypogonadotropic hypogonadism (HH) and Klinefelter syndrome (KS). Methods This was a combined study from two tertiary centers in Denmark and France analyzing INSL3 concentrations by LC–MS/MS. In total, 103 patients with HH and 82 patients with KS were grouped into treated (HH: n = 96; KS: n = 71) or untreated (HH: n = 7; KS: n = 11). Treatment modalities included testosterone and hCG. Serum concentrations and standard deviation (SD) scores of INSL3, total testosterone, and LH according to age and treatment were evaluated. Results In both HH and KS, INSL3 concentrations were low. In HH, INSL3 was low regardless of treatment, except for some hCG-treated patients with normal concentrations. In untreated HH, testosterone was low, while normal to high in most testosterone- and hCG-treated patients. In untreated KS, INSL3 and testosterone concentrations were low to normal, while in testosterone-treated KS, serum INSL3 was low in most patients. INSL3 SD scores were significantly lower in untreated HH than in untreated KS (p = 0.01). Conclusions The dichotomy between lower INSL3 and higher testosterone concentrations, particularly observed in hCG-treated patients with HH, confirms that INSL3 is a different marker of Leydig cell function than testosterone. However, the clinical application of INSL3 in males with hypogonadism remains unclear.
- Open Access
- 1 February 2020
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 182 (2) , 185-194
Congenital hypogonadotropic hypogonadism/Kallmann syndrome is associated with statural gain in both men and women: a monocentric study
Context: Congenital hypogonadotropic hypogonadism/Kallmann syndrome (CHH/KS) is a rare condition characterized by gonadotropin deficiency and pubertal failure. Adult height (AH) in patients with CHH/KS has not been well studied. Objective: To assess AH in a large cohort of patients with CHH/KS. Patients: A total of 219 patients (165 males, 54 females). Parents and siblings were included. Methods: AH was assessed in patients and family members. AH was compared to the general French population, mid parental target height (TH) and between patients and same-sex siblings. Delta height (∆H) was considered as the difference between AH and parental TH. ∆H was compared between patients and siblings, normosmic CHH and KS (CHH with anosmia/hyposmia), and according to underlying genetic defect. We examined the correlations between ∆H and age at diagnosis and therapeutically induced individual statural gain. Results: Mean AH in men and women with CHH/KS was greater than that in the French general population. Patients of both sexes had AH > TH. Males with CHH/KS were significantly, albeit moderately, taller than their brothers. ∆H was higher in CHH/KS compared to unaffected siblings (+6.2 ± 7.2 cm vs +3.4 ± 5.2 cm, P < 0.0001). ∆H was positively correlated with age at diagnosis. Neither olfactory function (normosmic CHH vs KS) nor specific genetic cause impacted ∆H. Individual growth during replacement therapy inversely correlated with the age at initiation of hormonal treatment (P < 0.0001). Conclusions: CHH/KS is associated with higher AH compared to the general population and mid-parental TH. Greater height in CHH/KS than siblings indicates that those differences are in part independent of an intergenerational effect.
- 1 February 2020
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 182 (2) , 185-194
Open AccessCongenital hypogonadotropic hypogonadism/Kallmann syndrome is associated with statural gain in both men and women: a monocentric study
Context: Congenital hypogonadotropic hypogonadism/Kallmann syndrome (CHH/KS) is a rare condition characterized by gonadotropin deficiency and pubertal failure. Adult height (AH) in patients with CHH/KS has not been well studied. Objective: To assess AH in a large cohort of patients with CHH/KS. Patients: A total of 219 patients (165 males, 54 females). Parents and siblings were included. Methods: AH was assessed in patients and family members. AH was compared to the general French population, mid parental target height (TH) and between patients and same-sex siblings. Delta height (∆H) was considered as the difference between AH and parental TH. ∆H was compared between patients and siblings, normosmic CHH and KS (CHH with anosmia/hyposmia), and according to underlying genetic defect. We examined the correlations between ∆H and age at diagnosis and therapeutically induced individual statural gain. Results: Mean AH in men and women with CHH/KS was greater than that in the French general population. Patients of both sexes had AH > TH. Males with CHH/KS were significantly, albeit moderately, taller than their brothers. ∆H was higher in CHH/KS compared to unaffected siblings (+6.2 ± 7.2 cm vs +3.4 ± 5.2 cm, P < 0.0001). ∆H was positively correlated with age at diagnosis. Neither olfactory function (normosmic CHH vs KS) nor specific genetic cause impacted ∆H. Individual growth during replacement therapy inversely correlated with the age at initiation of hormonal treatment (P < 0.0001). Conclusions: CHH/KS is associated with higher AH compared to the general population and mid-parental TH. Greater height in CHH/KS than siblings indicates that those differences are in part independent of an intergenerational effect.
- 1 December 2018
- Published by Elsevier in Journal of Affective Disorders
- Vol. 241, 22-28
Early weight gain predicts later weight gain in depressed patients treated with antidepressants: Findings from the METADAP cohort
- 1 December 2018
- Published by Elsevier in Journal of Affective Disorders
- Vol. 241, 22-28
Early weight gain predicts later weight gain in depressed patients treated with antidepressants: Findings from the METADAP cohort
- 1 November 2018
- Published by Elsevier in Journal of Affective Disorders
- Vol. 240, 230-236
Glycogen synthase kinase-3β genetic polymorphisms and insomnia in depressed patients: A prospective study
- 1 November 2018
- Published by Elsevier in Journal of Affective Disorders
- Vol. 240, 230-236
Glycogen synthase kinase-3β genetic polymorphisms and insomnia in depressed patients: A prospective study
- 24 August 2018
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 79 (4) , 243
Méfions-nous du NGS : attention aux faux-sens des incidentalomes génétiques des mutations NR3C1
- 24 August 2018
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 79 (4) , 243
Méfions-nous du NGS : attention aux faux-sens des incidentalomes génétiques des mutations NR3C1
- 1 June 2018
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 79 (3) , 98-106
Pathophysiology of Glucocorticoid Signaling
- 1 June 2018
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 79 (3) , 98-106
Pathophysiology of Glucocorticoid Signaling